Novo Nordisk A/S (NVO)
| Market Cap | 195.68B -35.7% |
| Revenue (ttm) | 50.57B +8.1% |
| Net Income | 18.81B +16.6% |
| EPS | 4.23 +16.8% |
| Shares Out | 4.44B |
| PE Ratio | 10.40 |
| Forward PE | 14.05 |
| Dividend | $1.29 (2.99%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 10,855,333 |
| Open | 44.05 |
| Previous Close | 43.75 |
| Day's Range | 42.86 - 44.22 |
| 52-Week Range | 35.12 - 81.44 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 46.91 (+9.2%) |
| Earnings Date | May 6, 2026 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $46.91, which is an increase of 9.20% from the latest price.
News
Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA...
(RTTNews) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business; Absci, ahead o...
Novo Nordisk AS (NVO) Stock Up 4.2% and Still Undervalued -- GF Score: 74/100
Novo Nordisk AS (NVO) Stock Up 4.2% and Still Undervalued -- GF Score: 74/100
NVO: Novo Nordisk Partners with Veru for Clinical Study Supply Agreement
NVO: Novo Nordisk Partners with Veru for Clinical Study Supply Agreement
Novo Nordisk (NVO) Partners with Veru, Boosting Stock Performance
Novo Nordisk (NVO) Partners with Veru, Boosting Stock Performance
Veru pact with Novo ‘significant event,’ says Canaccord
Canaccord keeps a Buy rating on Veru (VERU) with a $25 price target after the company disclosed a supply agreement with Novo Nordisk (NVO) for Wegovy. The news is a…
Veru announces clinical supply agreement with Novo Nordisk
In a regulatory filing, Veru (VERU) announced that on June 2, the company entered into a clinical supply agreement with Novo Nordisk A/S (NVO) in conjunction with the company’s Phase…
Here's What I Think Is Really Going on With Novo Nordisk Stock
Novo Nordisk lost momentum in the GLP-1 market. The company's deep pipeline could allow it to bounce back.
Novo Nordisk is taking its Wegovy pill beyond the U.S.
Novo Nordisk is taking its Wegovy pill beyond the U.S.
Novo Nordisk (NVO) Launches Wegovy in UAE Following Regulatory Approval
Novo Nordisk (NVO) Launches Wegovy in UAE Following Regulatory Approval
Novo Nordisk Launches Wegovy in UAE, Aiming for Global Expansion
Novo Nordisk Launches Wegovy in UAE, Aiming for Global Expansion
Focus: GLP-1 drugs may have a beneficial effect across many types of cancer
A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide protection against many types of cancer.
Novo Nordisk launches Wegovy in UAE
Novo Nordisk is launching its weight-loss drug Wegovy in the United Arab Emirates, it said in a statement on Wednesday.
Novo Nordisk rolls out Wegovy pill in the UAE — its first market outside the U.S.
Novo Nordisk is launching weight loss pill Wegovy in the United Arab Emirates, the Danish drugmaker said Wednesday. It marks the pill's first launch outside the U.S. market.
Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE
The United Arab Emirates becomes the second country to offer the pill after the drugmaker launched it in the U.S. in early January.
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
Novo Nordisk is launching Wegovy® pill in the UAE, the first country outside the US, to make the Wegovy® pill available to people living with obesity
Exclusive: Cigna drops coverage of GLP-1 obesity drugs for its own employees
Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee health plan effective July 1, according to materials viewe...
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down
An upcoming trial result could change how investors think about the weight-loss drug market.
A Look at Novo Nordisk AS (NVO) After 3.3% Decline -- GF Value $137.86 vs Price $44.07
A Look at Novo Nordisk AS (NVO) After 3.3% Decline -- GF Value $137.86 vs Price $44.07
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 1 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 ...
Novo Nordisk (NVO) Gains Ground Against Eli Lilly with Wegovy Pill Success
Novo Nordisk (NVO) Gains Ground Against Eli Lilly with Wegovy Pill Success
Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now
Eli Lilly is performing very well as a business right now, which should please shareholders. Novo Nordisk has fallen behind Eli Lilly in the GLP-1 space and has warned that 2026 will be a difficult ye...
France Approves Reimbursement for Novo Nordisk (NVO) and Eli Lilly (LLY) Weight Loss Drugs
France Approves Reimbursement for Novo Nordisk (NVO) and Eli Lilly (LLY) Weight Loss Drugs
France becomes first EU country to reimburse anti-obesity drugs
France will reimburse the cost of weight-loss drugs prescribed to severely obese patients from mid-June in a first for a European Union country, Health Minister Stephanie Rist said on Thursday. Novo ...
Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?
Novo Nordisk is outpacing Eli Lilly in the oral weight loss market. However, Eli Lilly is still the overall leader in chronic weight management.
Cboe data shows mixed options sentiment in Novo Nordisk with shares up 1.46%
Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares up 64c, or 1.46%, near $44.84. Options volume relatively light with 28k contracts traded and calls leading puts…